Palisades Investment Partners Acquires $5.26M Stake in Travere Therapeutics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 24 2026
0mins
Source: Fool
- New Investment Position: Palisades Investment Partners initiated a new position in Travere Therapeutics by acquiring 137,768 shares valued at $5.26 million in Q4 2025, indicating a bullish outlook on the company's growth potential.
- Strong Stock Performance: As of January 19, 2026, Travere Therapeutics shares were priced at $27.87, reflecting a 50.89% increase over the past year, outperforming the S&P 500 by 34.01 percentage points, showcasing market recognition of its potential value.
- Significant Revenue Growth: The sales of Travere's FILSPARI drug surged 155% year-over-year to $90.9 million in Q3 2023, contributing to a total revenue increase from $62.9 million to $164.9 million, demonstrating strong market demand for its products.
- FDA Review Catalyst: With the FDA reviewing Travere's FILSPARI for potential approval in specific disease treatments, Palisades' investment reflects optimism about Travere's future market performance, especially with anticipated growth following potential FDA approval.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TVTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TVTX
Wall Street analysts forecast TVTX stock price to fall
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 47.080
Low
31.00
Averages
42.89
High
49.00
Current: 47.080
Low
31.00
Averages
42.89
High
49.00
About TVTX
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Long-term Results of FILSPARI Show Significant Efficacy
- Efficacy Durability: In a five-year study, patients treated with FILSPARI maintained durable reductions in proteinuria, achieving clinically meaningful low proteinuria thresholds, demonstrating the drug's long-term effectiveness in treating FSGS.
- Rapid Transition Effects: Patients transitioning from maximum labeled dose irbesartan to FILSPARI during the open-label extension experienced rapid and sustained reductions in proteinuria, indicating that FILSPARI's efficacy is comparable to those who initiated treatment during the double-blind period, reinforcing its role as foundational care.
- Clinical Outcome Superiority: At the end of the double-blind period, the complete remission rate for FILSPARI patients was 18.5% compared to 7.5% for irbesartan, with partial remission rates of 69.0% and 50.8%, respectively, highlighting FILSPARI's significant advantages in treating FSGS.
- Good Safety Profile: Over five years of follow-up, FILSPARI was generally well tolerated, with a safety profile consistent with previous findings, further enhancing confidence in its clinical application.
See More
Travere Licenses Civorebrutinib from Everest Medicines, Potential Best-in-Class Treatment
- Licensing Agreement Details: Travere Therapeutics has entered into a licensing agreement with China's Everest Medicines, paying $112.5 million upfront for exclusive rights to develop and sell Civorebrutinib in the U.S. and other markets, which is expected to significantly enhance its market position in rare kidney disease treatments.
- Optimistic Clinical Outlook: Early clinical studies indicate that Civorebrutinib effectively lowers harmful antibodies and excess protein in urine, helps more patients achieve remission, and maintains stable kidney function for up to a year, showcasing its potential to become a 'best-in-class' treatment.
- Positive Market Reaction: Although Travere's stock initially fell 6% following the announcement, H.C. Wainwright raised its price target from $57 to $67, implying a potential upside of 49%, reflecting market optimism regarding the drug's prospects.
- Future Research Plans: Travere plans to further study Civorebrutinib in patients with primary membranous nephropathy and certain forms of focal segmental glomerulosclerosis and minimal change disease, with potential milestone payments of up to $1.03 billion and ongoing royalties if the drug successfully reaches the market.
See More
Travere Therapeutics and Everest Medicines Sign $1.1B Licensing Agreement
- Agreement Details: Travere Therapeutics (TVTX) has entered into a licensing and collaboration agreement worth up to $1.1 billion with China's Everest Medicines, securing exclusive development and commercialization rights for civorebrutinib, aimed at rare immune-mediated kidney diseases, highlighting the company's strategic expansion in the biopharma sector.
- Upfront and Milestone Payments: Under the terms, Travere will receive $112.5 million upfront and up to $1.03 billion in milestone payments, providing substantial funding for R&D efforts and advancing civorebrutinib across five indications.
- Market Potential and Royalties: Everest Medicines will be eligible for tiered royalties ranging from high single-digit to double-digit percentages based on future sales, ensuring a revenue stream that could foster further collaboration in other markets.
- US-China Collaboration Trend: Despite geopolitical tensions, U.S. biopharma companies are increasingly pursuing licensing deals with China, reflecting confidence in the Chinese biopharma market and the potential for mutual growth opportunities.
See More
Travere Therapeutics Grants Equity Inducements to New Employees
- Equity Incentive Program: On May 10, 2026, Travere Therapeutics granted inducement equity awards totaling 48,800 shares to four new employees, comprising 18,000 inducement stock options and 30,800 inducement restricted stock units (RSUs), aimed at attracting new talent to the company.
- Stock Option Details: The stock options have an exercise price of $43.51 per share, based on the closing price on the next trading day after the grant date, with a 10-year term and a four-year vesting schedule, where 25% vests after one year and the remaining 75% vests monthly over the following 36 months, ensuring employee retention.
- RSU Vesting Structure: The inducement RSUs also vest over four years, with 25% vesting each year, which not only incentivizes long-term employee commitment but also enhances the company's attractiveness to new hires, complying with Nasdaq Listing Rule requirements.
- Company Mission and Vision: Travere Therapeutics is dedicated to providing urgently needed treatment options for patients with rare diseases, with a global team collaborating with the rare disease community to develop and deliver life-changing therapies, highlighting the strategic significance of the company in the biopharmaceutical sector.
See More
Roy D. Baynes Sells Shares in Travere Therapeutics Under 10b5-1 Plan
- Transaction Overview: Roy D. Baynes, Director at Travere Therapeutics, reported the exercise and immediate sale of 4,500 common shares for approximately $210,000, indicating a need for liquidity amidst his ongoing stock management strategy.
- Ownership Change Analysis: Following this transaction, Baynes's direct holdings decreased by 4,500 shares, representing a 10.71% reduction, leaving him with 37,500 shares, which suggests a strategic shift in his ownership stake in the company.
- Transaction Structure Insight: The sale involved exercising fully vested options at a strike price of $18.27 and selling at $46.65, netting around $127,700, which highlights his strategy of capitalizing on high market prices.
- Investor Signal: Although this transaction was executed under a 10b5-1 plan adopted in November 2025, it should not be interpreted as a negative signal regarding Travere's recent performance, as Baynes still retains shares valued at approximately $1.6 million.
See More
Director Roy D. Baynes Sells Shares of Travere Therapeutics
- Stock Option Exercise: On May 5, 2026, Roy D. Baynes exercised 4,500 stock options and sold them at a weighted average price of approximately $46.65 per share, totaling around $210,000, which reduced his direct holdings from 42,000 to 37,500 shares, indicating a strategic adjustment in his ownership stake.
- Transparent Trading Plan: This transaction was executed under a 10b5-1 plan adopted by Baynes in November 2025, indicating that the sale was unrelated to any developments at Travere in May 2026, thus preventing misinterpretation of the sale as a directional signal and ensuring compliance and transparency in the process.
- Market Performance Analysis: At the time of the transaction, Travere's stock traded within a 52-week range of $13.88 to $48.61, with the sale occurring near the top of this range, reflecting Baynes's strategy to reduce his position at a high point, even as he retains approximately $1.6 million worth of shares.
- Investor Caution: Despite Baynes's sale potentially raising eyebrows, the Motley Fool analyst team noted that Travere Therapeutics was not included in their list of the 10 best stocks to buy, suggesting that investors should exercise caution when considering purchases in the current market environment.
See More
Long-term Results of FILSPARI Show Significant Efficacy
- Efficacy Durability: In a five-year study, patients treated with FILSPARI maintained durable reductions in proteinuria, achieving clinically meaningful low proteinuria thresholds, demonstrating the drug's long-term effectiveness in treating FSGS.
- Rapid Transition Effects: Patients transitioning from maximum labeled dose irbesartan to FILSPARI during the open-label extension experienced rapid and sustained reductions in proteinuria, indicating that FILSPARI's efficacy is comparable to those who initiated treatment during the double-blind period, reinforcing its role as foundational care.
- Clinical Outcome Superiority: At the end of the double-blind period, the complete remission rate for FILSPARI patients was 18.5% compared to 7.5% for irbesartan, with partial remission rates of 69.0% and 50.8%, respectively, highlighting FILSPARI's significant advantages in treating FSGS.
- Good Safety Profile: Over five years of follow-up, FILSPARI was generally well tolerated, with a safety profile consistent with previous findings, further enhancing confidence in its clinical application.
See More
Travere Licenses Civorebrutinib from Everest Medicines, Potential Best-in-Class Treatment
- Licensing Agreement Details: Travere Therapeutics has entered into a licensing agreement with China's Everest Medicines, paying $112.5 million upfront for exclusive rights to develop and sell Civorebrutinib in the U.S. and other markets, which is expected to significantly enhance its market position in rare kidney disease treatments.
- Optimistic Clinical Outlook: Early clinical studies indicate that Civorebrutinib effectively lowers harmful antibodies and excess protein in urine, helps more patients achieve remission, and maintains stable kidney function for up to a year, showcasing its potential to become a 'best-in-class' treatment.
- Positive Market Reaction: Although Travere's stock initially fell 6% following the announcement, H.C. Wainwright raised its price target from $57 to $67, implying a potential upside of 49%, reflecting market optimism regarding the drug's prospects.
- Future Research Plans: Travere plans to further study Civorebrutinib in patients with primary membranous nephropathy and certain forms of focal segmental glomerulosclerosis and minimal change disease, with potential milestone payments of up to $1.03 billion and ongoing royalties if the drug successfully reaches the market.
See More
Travere Therapeutics and Everest Medicines Sign $1.1B Licensing Agreement
- Agreement Details: Travere Therapeutics (TVTX) has entered into a licensing and collaboration agreement worth up to $1.1 billion with China's Everest Medicines, securing exclusive development and commercialization rights for civorebrutinib, aimed at rare immune-mediated kidney diseases, highlighting the company's strategic expansion in the biopharma sector.
- Upfront and Milestone Payments: Under the terms, Travere will receive $112.5 million upfront and up to $1.03 billion in milestone payments, providing substantial funding for R&D efforts and advancing civorebrutinib across five indications.
- Market Potential and Royalties: Everest Medicines will be eligible for tiered royalties ranging from high single-digit to double-digit percentages based on future sales, ensuring a revenue stream that could foster further collaboration in other markets.
- US-China Collaboration Trend: Despite geopolitical tensions, U.S. biopharma companies are increasingly pursuing licensing deals with China, reflecting confidence in the Chinese biopharma market and the potential for mutual growth opportunities.
See More
Travere Therapeutics Grants Equity Inducements to New Employees
- Equity Incentive Program: On May 10, 2026, Travere Therapeutics granted inducement equity awards totaling 48,800 shares to four new employees, comprising 18,000 inducement stock options and 30,800 inducement restricted stock units (RSUs), aimed at attracting new talent to the company.
- Stock Option Details: The stock options have an exercise price of $43.51 per share, based on the closing price on the next trading day after the grant date, with a 10-year term and a four-year vesting schedule, where 25% vests after one year and the remaining 75% vests monthly over the following 36 months, ensuring employee retention.
- RSU Vesting Structure: The inducement RSUs also vest over four years, with 25% vesting each year, which not only incentivizes long-term employee commitment but also enhances the company's attractiveness to new hires, complying with Nasdaq Listing Rule requirements.
- Company Mission and Vision: Travere Therapeutics is dedicated to providing urgently needed treatment options for patients with rare diseases, with a global team collaborating with the rare disease community to develop and deliver life-changing therapies, highlighting the strategic significance of the company in the biopharmaceutical sector.
See More
Roy D. Baynes Sells Shares in Travere Therapeutics Under 10b5-1 Plan
- Transaction Overview: Roy D. Baynes, Director at Travere Therapeutics, reported the exercise and immediate sale of 4,500 common shares for approximately $210,000, indicating a need for liquidity amidst his ongoing stock management strategy.
- Ownership Change Analysis: Following this transaction, Baynes's direct holdings decreased by 4,500 shares, representing a 10.71% reduction, leaving him with 37,500 shares, which suggests a strategic shift in his ownership stake in the company.
- Transaction Structure Insight: The sale involved exercising fully vested options at a strike price of $18.27 and selling at $46.65, netting around $127,700, which highlights his strategy of capitalizing on high market prices.
- Investor Signal: Although this transaction was executed under a 10b5-1 plan adopted in November 2025, it should not be interpreted as a negative signal regarding Travere's recent performance, as Baynes still retains shares valued at approximately $1.6 million.
See More
Director Roy D. Baynes Sells Shares of Travere Therapeutics
- Stock Option Exercise: On May 5, 2026, Roy D. Baynes exercised 4,500 stock options and sold them at a weighted average price of approximately $46.65 per share, totaling around $210,000, which reduced his direct holdings from 42,000 to 37,500 shares, indicating a strategic adjustment in his ownership stake.
- Transparent Trading Plan: This transaction was executed under a 10b5-1 plan adopted by Baynes in November 2025, indicating that the sale was unrelated to any developments at Travere in May 2026, thus preventing misinterpretation of the sale as a directional signal and ensuring compliance and transparency in the process.
- Market Performance Analysis: At the time of the transaction, Travere's stock traded within a 52-week range of $13.88 to $48.61, with the sale occurring near the top of this range, reflecting Baynes's strategy to reduce his position at a high point, even as he retains approximately $1.6 million worth of shares.
- Investor Caution: Despite Baynes's sale potentially raising eyebrows, the Motley Fool analyst team noted that Travere Therapeutics was not included in their list of the 10 best stocks to buy, suggesting that investors should exercise caution when considering purchases in the current market environment.
See More
